National Academies Press: OpenBook

The Children's Vaccine Initiative: Continuing Activities (1995)

Chapter: TRENDS IN THE GLOBAL VACCINE SITUATION

« Previous: BRINGING CLARITY TO THE CVI VISION
Suggested Citation:"TRENDS IN THE GLOBAL VACCINE SITUATION." Institute of Medicine. 1995. The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press. doi: 10.17226/9103.
×

TRENDS IN THE GLOBAL VACCINE SITUATION

Industry Characteristics

Concerns about the anticipated high cost of some newer vaccines—especially those produced with so-called conjugation technology—as well as fears of price hikes for the current set of EPI vaccines 37 prompted the United Nations Children’s Fund (UNICEF) and the WHO to commission an analysis of the commercial aspects of global vaccine supply.38 The analysis focused on the firms that sell vaccine to UNICEF.39 Among its many findings, the study revealed that vaccine manufacturing is a largely fixed-cost activity (Box 5). That is, to a greater extent than in many other sectors, production efficiency in the vaccine business rises dramatically with increasing volume. This means that relatively fewer additional man-hours are needed for a given boost in production volume. This advantage holds true only if the manufacturing facility is appropriately sized from the start, however.

There has also been a general consolidation of the worldwide vaccine industry, reflected by strategic alliances between and among companies on both sides of the Atlantic. According to industry officials, these mergers are driven largely by the desire to access technology and share intellectual property in order to develop combination vaccines. What impact these mergers may have on industry involvement in the CVI is unclear. For their part, U.S. biotechnology companies involved in vaccine R&D report that they require generally lower profit margins than big industry (because of lower fixed overhead costs) and have a greater interest in pursuing products of potential use in the developing world. However, in order to attract investors, biotechnology firms may be even more dependent than large vaccine makers on evidence of markets for prospective vaccine products.

Local Production and Self-Sufficiency

Although UNICEF and others have been concerned that rising vaccine demand and prices would exceed the ability of the fund to provide EPI vaccines to the developing world, this appears not to be the case. UNICEF purchases

37  

EPI vaccines target seven diseases: diphtheria, pertussis, tetanus, tuberculosis, polio, measles, and hepatitis B.

38  

The study, a summary of which was published by UNICEF, was conducted by Mercer Management Consulting.

39  

U.S. vaccine manufacturers, who have not sold vaccine to UNICEF since the early 1980s, were not included in the analysis.

Suggested Citation:"TRENDS IN THE GLOBAL VACCINE SITUATION." Institute of Medicine. 1995. The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press. doi: 10.17226/9103.
×

BOX 5 The Economics of Vaccine Manufacturing

  • Three cost categories: variable, batch fixed, site fixed

  • Fixed-cost categories represent about 85 percent of manufacturing expense

  • Marginal cost per dose of producing additional vaccine is significantly lower than the full cost per dose of lower production volume

  • UNICEF purchases cover suppliers’ fully marginal and marginal production costs

SOURCE: Adapted from summary of Mercer study of commercial vaccinesupply, UNICEF, 1994.

some 525 million doses of EPI vaccines each year, equal to about 15 percent of the worldwide sales of these products. The fund is paying more per dose for these vaccines now than in the past, but this is due mainly to the decline in value of the U.S. dollar. In fact, over the last decade, the prices of vaccines purchased by UNICEF have remained relatively stable. Worldwide, the total production of EPI vaccines has been increasing at a steady 7 percent per annum; however, the volume of UNICEF-purchased EPI vaccines has been declining since 1990, primarily in response to rising local production of these vaccines. According to Mercer Management Consulting, local production has risen at an annual rate of 10 percent over the last 10 years. Indigenous production facilities, including many in the developing world, have become major sources of vaccine in the world. For instance, India and China together account for more than two-thirds of all local production of EPI vaccines.

An additional factor altering the landscape of the global vaccine market is the move toward self-sufficiency. About 70 percent of EPI vaccines now are purchased by the nations that use them. Countries buying their own vaccine may be motivated by any number of factors, including national pride and the desire for an inexpensive, secure supply of vaccine. Part of this trend is the result of the Vaccine Independence Initiative. Launched by the UNICEF and the U.S. Agency for International Development in 1992, the initiative is a revolving fund that helps countries purchase childhood vaccines using local currency. UNICEF then uses these monies to administer its programs in the purchasing country. The

Suggested Citation:"TRENDS IN THE GLOBAL VACCINE SITUATION." Institute of Medicine. 1995. The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press. doi: 10.17226/9103.
×
Page 29
Suggested Citation:"TRENDS IN THE GLOBAL VACCINE SITUATION." Institute of Medicine. 1995. The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press. doi: 10.17226/9103.
×
Page 30
Next: RESHAPING THE EPI »
The Children's Vaccine Initiative: Continuing Activities Get This Book
×
MyNAP members save 10% online.
Login or Register to save!
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!